Cellular Matrix -Model A-CP-HA -Class III CE Certified Medical Devices

Hyaluronic acid is a major component of synovial fluid contributing to joint homeostasis.

• 25 years of clinical experience shows pain relief and functional improvement lasting 6 to 12 months in OA patients.
• Plays a major role in viscosupplementation and pain relief in OA.5
• The network of HA chains generates an ideal cell-friendly matrix when combined with PRP.6

Hyaluronic acid improves the activity of several molecules contained in platelet-rich plasma to provide additional benefits to OA patients1.
Both PRP and HA have been extensively used to improve lubrication, modulate inflammation and modify the joint catabolic micro-environment, aiming not only to reduce clinical symptoms, but also to slow down OA progression2.

When PRP and HA are used in combination these effects are enhanced and prolonged. HA creates a bioactive scaffolding in which the platelets progressively release their growth factors. RegenPRP does not negatively affect the mechanical, elastic or viscous properties of HA1.

• RegenPRP^® is standardized, leucocyte reduced and easily reproducible
  Regen Lab specific separating gel technology guarantees minimal variability
• Platelets recovery in CM-PRP-HA >70%
• High platelet quality
  Viable & functional platelets
• Full plasma recovery
  No loss of plasma growth factors and fibrinogen
• Leucocyte reduced PRP Depletion ~ 94.3% of pro-inflammatory granulocytes, leaving mainly lymphocytes and monocytes
• Virtually no red blood cells
  Depletion of ~ 99.5% of erythrocytes

A-CP-HA Tube Properties benefit
BLOOD SAMPLE VOL PER TUBE
6 ml

PRP VOL PER TUBE
~3 ml of PRP combined with 2 ml of HA

PLATELET RECOVERY
> 70 %

GRANULOCYTE DEPLETION
94.3 %

RED BLOOD CELL DEPLETION
99.5 %

• User-independent standardized preparation
• Minimum volume of blood required
• Safe closed-circuit system
• Mechanical isolation of PRP using a biologically inert gel after a 5-minute centrifugation
• Reversible anticoagulation with a pharmaceutical grade solution of sodium citrate at pH 7
• Minimal learning curve and ease of use
• Operationally and clinically efficient process
• Facilitates and streamlines routine practice

• Certified technology for the preparation of RegenPRP^® combined with hyaluronic acid (HA) (CM-PRP-HA)
• Contains 2 ml of non-crosslinked HA at a concentration of 20 mg/ml (40 mg total)
• HA produced by bacterial fermentation, thus free of animal proteins

• Demonstrated safety and efficacy
• Evidence-based outcomes for numerous therapeutic indications
• Large number of clinical studies, with over 200 publications